EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 3.0

GDF15: Immunomodulatory Role in Hepatocellular Carcinoma Pathogenesis and Therapeutic Implications

Yi-Ning Du, Jin-Wei Zhao

Journal of Hepatocellular Carcinoma · 2024-06 · Volume 11 · 1171-1183

DOI: 10.2147/jhc.s471239 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Hepatocellular Carcinoma, 2024-06. Verfasst von Yi-Ning Du und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Sciences, Li Ka-shing School of Medicine, University of Hong Kong, Hong Kong, People's Republic of China. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 115 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related deaths globally and the sixth most common cancer worldwide. Evidence shows that growth differentiation factor 15 (GDF15) contributes to hepatocarcinogenesis through various mechanisms. This paper reviews the latest insights into the role of GDF15 in the development of HCC, its role in the immune microenvironment of HCC, and its molecular mechanisms in metabolic dysfunction associated steatohepatitis (MASH) and metabolic associated fatty liver disease (MAFLD)-related HCC. Additionally, as a serum biomarker for HCC, diagnostic and prognostic value of GDF15 for HCC is summarized. The article elaborates on the immunological effects of GDF15, elucidating its effects on hepatic stellate cells (HSCs), liver fibrosis, as well as its role in HCC metastasis and tumor angiogenesis, and its interactions with anticancer drugs. Based on the impact of GDF15 on the immune response in HCC, future research should identify its signaling pathways, affected immune cells, and tumor microenvironment interactions. Clinical studies correlating GDF15 levels with patient outcomes can aid personalized treatment. Additionally, exploring GDF15-targeted therapies with immunotherapies could improve anti-tumor responses and patient outcomes.

Schlagwörter

Stichwörter der Autor:innen

GDF15HCCgrowth differentiation factor 15hepatocellular carcinomaimmune suppressionimmunotherapy

Autor:innen und Institutionen

  • Department of Medical Sciences, Li Ka-shing School of Medicine, University of Hong Kong, Hong Kong, People's Republic of China.
  • Department of Hepatopancreatobiliary Surgery, Second Hospital of Jilin University, Jilin University, Changchun, Jilin Province, People's Republic of China.

Zitieren

APA

Du, Y. N., & Zhao, J. W. (2024). GDF15: Immunomodulatory Role in Hepatocellular Carcinoma Pathogenesis and Therapeutic Implications. Journal of Hepatocellular Carcinoma, Volume 11, 1171-1183. https://doi.org/10.2147/jhc.s471239

Vancouver

Du YN, Zhao JW. GDF15: Immunomodulatory Role in Hepatocellular Carcinoma Pathogenesis and Therapeutic Implications. Journal of Hepatocellular Carcinoma. 2024;Volume 11:1171-1183. doi:10.2147/jhc.s471239

BibTeX
@article{Du2024,
  author = {Du, Yi-Ning and Zhao, Jin-Wei},
  title = {GDF15: Immunomodulatory Role in Hepatocellular Carcinoma Pathogenesis and Therapeutic Implications},
  journal = {Journal of Hepatocellular Carcinoma},
  year = {2024},
  volume = {Volume 11},
  pages = {1171--1183},
  doi = {10.2147/jhc.s471239}
}
Kostenlos starten →